echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: Prognosis for hematopoietic cell transplantation treatment for Wiskott-Aldrich syndrome

    Blood: Prognosis for hematopoietic cell transplantation treatment for Wiskott-Aldrich syndrome

    • Last Update: 2020-06-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Aldridge syndrome (WAS) is an X-chromosome chain disease caused by mutations in the WAS gene that can lead to platelet reduction, eczema, recurrent infections, autoimmune diseases and malignant tumorsHematopoietic Cell Transplantation (HCT) is the main treatment designed to correct potential immunodeficiency and platelet reductionthe prognosis of HCT improved over time, especially in patients with siblings and unrelated donors that matched HLAThis study reported on the prognosis of 129 WAS patients treated with HCT at 29 combination centers for primary immunodeficiency therapy from 2005 to 2015The median age at HCT is 1.2 yearsMost patients (65%) underwent bone marrow removal-based conditioningMedian follow-up was 4.5 years, with an overall 5-year survival rate (OS) of 91%The five-year OS performed HCT was significantly better (94 percent vs 66 percent) compared to patients who performed HCT at the age of 5OS is very good (90%) even in cord blood receptors, regardless of donor typeThe regulatory intensity does not affect OS, but is related to hcT post-donor T-cell and myelin cell transplantationIn particular, patients who received a low-intensity treatment based on fluodabin/mefalenarewered to be 50% more likely to have donor bone marrow chinos in the early stages of HCT, the platelet count of recipients performing whole myelin cell transplantation was higher than those with a low proportion (5-49%)myelin cell transplantall in all, was the HCT prognosis of WAS has improved from previous reports since 2005A high proportion of donor myelin cell transplantation is essential for platelet reconstruction
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.